Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells

By sjmartinez • March 13, 2023

Li S, Wang CS, Montel-Hagen A, Chen HC, Lopez S, Zhou O, Dai K, Tsai S, Satyadi W, Botero C, Wong C, Casero D, Crooks GM, Seet CS. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell Rep. 2023 Mar 10;42(3):112241. doi: 10.1016/j.celrep.2023.112241. Epub ahead of print. PMID: 36906850.

Tags: adoptive cell therapy, cancer immunotherapy, chimeric antigen receptor, CP, Hematology/Oncology, Immunology, innate lymphoid cells, pluripotent stem cells, Publications, Stem cell research, T cell development

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors

McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie ...

Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1Inhibitor

Chawla SP, Olevsky O, Iyengar G, Brigham DA, Omelchenko N, Thomas S, Suryamohan K, Foshag L, Hall FL, Gordon EM. Early-stage CCNG1+ HR+ HER2+ Invasive Breast ...

Year 2. May 30. Educational Excellence.

As we celebrate the accomplishments of our trainees and the students at the David Geffen School of Medicine (DGSOM) this graduation season, I am reminded ...